January 2, 2024 7:50am

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Pre-open Indications: 2 Positive, 2 Negative and 1 Sell into Strength Indications

If you want facts to interpret share pricing realities to save your portfolio for cautious decisions, bookmark this site!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I make a commitment to provide need-to-know “facts in evidence” as an equity’s volatility is one tactical signal for stocks. My thesis is important in trying to distinguish the temporary from real pricing digression or progress.

 

The pre-open Dow futures are DOWN -0.54% or (-206 points), the S&P is DOWN -0.70% or (-33 points) as the Nasdaq is DOWN -0.98% (-168 points)

Stock futures were lower Tuesday, the first trading day of the year, as interest rates rebounded slightly and investors take some money off the table,

European stocks slipped into the red,

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed Friday with the Dow closed DOWN -20.56 points or -0.05%, the S&P closed DOWN -13.52 points or -0.28% while the Nasdaq closed DOWN -83.78 points or -0.56%

Economic Data Docket: S&P Global US Services PMI, December, final (48.4 expected, 48.2previously); MBA Mortgage Applications, week ending December 29

 

Friday, RegMed Investors (RMi) Closing Bell: “the last session’s hourglass slips empty” …  https://www.regmedinvestors.com/articles/13264

 

Q1/24: 1 holiday and its 1st session

Q4:  

  • December – 1 holiday, 10 positive and 10 negative closes
  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Potential …

Positive Indications:

Friday’s closing price, some Thursday, Wednesday, Tuesday and Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Ionis Pharmaceuticals (IONS) closed up +$0.09 after Thursday’s +$0.34, Wednesday’s -$1.14 and Tuesday’s +$0.11 with a positive +$0.85 or +1.68% aftermarket indication.

Prime Medine (PRME) closed down -$0.69 after Thursday’s +$0.14, Wednesday’s +$0.21 and Tuesday’s -$0.02 with a positive +$0.29 or +3.27% pre-open indication

 

Sell into Strength Indication;

Friday’s closing price, some Thursday, Wednesday, Tuesday and Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed up +$0.89 after Thursday’s -$1.49, Wednesday’s +$2.03 and Tuesday’s +$1.98 with a positive +$1.75 or +1.90% pre-open indication.

 

Negative Indications:

Friday’s closing price, some Thursday, Wednesday, Tuesday and Monday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed down -$1.70 after Thursday’s -$0.66, Wednesday’s -$0.37 and Tuesday’s +$1.66 with a negative -$0.11 or -0.18% pre-open indication.

MiMedx (MDXG) closed down -$0.13 with a negative -$0.57 or -6.50% pre-open indication after a suspension of its KOA (knee osteoarthritis) realignment which is expected to cost $5 million in wind down expenses and save $25 million per year in costs.

 

The BOTTOM LINE: 12/29/23 ended with my message of: “Looking toward 2024 with one word – recalibration i.e., a change in the way you do or think about something – markets and the cell and gene therapy sector.”

  • Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What RMi provides is a trusted source of share pricing intelligence
  • As a quantamental plotter which equates to a quantitative analyst straddling fundamental stock picking to produce better results for investors; the term “quantamental,” blends the two styles setting forth my difference retail, trading and multiple investor categories.

 

Cell and gene therapy sector sentiment indicators show elevated negativity while the Nasdaq is 6.9% above its 50-day line, easing off from a few days ago. But it wouldn't take much to see the composite look extended again.

Last week:

  • Friday closed negative with 7 incliners, 28 decliners and 0 flat
  • Thursday closed negative with 17 incliners, 18 decliners and 0 flat
  • Wednesday closed negative with 16 incliners, 19 decliners and 0 flat
  • Tuesday closed positive with 25 incliners, 8 decliners and 2 flats
  • Monday (12/25) was Christmas

There could be some wobbles in early January, as volume returns and some tax selling takes place. So, investors may want to see how that shakes out. But they should be looking for new buying opportunities, and reviewing past trades. <IBD>

  • The first week of trading in 2024 will instantly put the rally to the test with a crucial December jobs report slated for release on Friday morning.
  • The report is expected to show 168,000 nonfarm payroll jobs were added to the US economy last month while the unemployment rate ticked higher to 3.8%. In November, the US economy added 199,000 jobs while the unemployment rate unexpectedly declined to 3.7%. <Bloomberg>
  • The economic calendar will also feature meeting notes from the Fed, the latest update on job openings and fresh data on activity in the manufacturing and services sectors.

 

News of financing, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!

An appropriate quote that could reinforce what I have written (after the fact), ““The biggest actual risk facing equities isn’t the Fed or [European Central Bank] not cutting as much as anticipated but instead that [earnings per share] suffers a larger than expected decline amid an environment of cooler growth and waning price power.” <Adam Crisafulli, Vital Knowledge>.

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.